News

bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.

The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

We were delighted to welcome CEO National Resilience Inc. Rahul Singhvi who visited our labs and office space.

bit.bio appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

Funding raised to accelerate and expand cell therapy pipeline.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.

MP Anthony Browne visits bit.bio's labs and offices to officially open facilities.